Know Cancer

or
forgot password

Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects


Phase 2
18 Years
N/A
Not Enrolling
Both
HIV Infections

Thank you

Trial Information

Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects

Inclusion Criteria

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Virologic response after 2 weeks of functional monotherapy

Principal Investigator

Boehringer Ingelheim Study Coordinator

Investigator Role:

Study Chair

Investigator Affiliation:

Boehringer Ingelheim Pharmaceuticals

Authority:

United States: Food and Drug Administration

Study ID:

1182.52

NCT ID:

NCT00275444

Start Date:

March 2002

Completion Date:

August 2003

Related Keywords:

  • HIV Infections
  • HIV Infections
  • Acquired Immunodeficiency Syndrome

Name

Location

Duke University Medical CenterDurham, North Carolina  27710
Ohio State University Medical CenterColumbus, Ohio  43210
University of LouisvilleLouisville, Kentucky  40202
Atlanta Va Medical CenterDecatur, Georgia  30033
Washington UniversitySt. Louis, Missouri  63110
David Geffen School of Medicine at UCLALos Angeles, California  90095
Wake Forest University Baptist Medical CenterWinston-Salem, North Carolina  27157
Boehringer Ingelheim Investigational SitePhoenix, Arizona  
Boehringer Ingelheim Investigational SiteFountain Valley, California  
Living Hope Clinical Trials, Inc.Long Beach, California  
Vincent Lombardi Cancer CenterWashington, D.C., District of Columbia  
Therafirst Medical CenterFort Lauderdale, Florida  
1501 N.W. 9th AveMiami, Florida  
Boehringer Ingelheim Investigational SiteOrlando, Florida  
Hillsborough County Health Dept.Tampa, Florida  
Boehringer Ingelheim Investigational SiteAtlanta, Georgia  
Mercer University School of MedicineMacon, Georgia  
CORE CenterChicago, Illinois  
Rush-Presbytarian-St Luke's Medical CenterChicago, Illinois  
HIV Outpatient Program (H.O.P)New Orleans, Louisiana  
John's Hopkins UniversityBaltimore, Maryland  
Boehringer Ingelheim Investigational SiteBoston, Massachusetts  
Community Research Initiative of New EnglandSpringfield, Massachusetts  
University of Michigan Health SystemAnn Arbor, Michigan  
Boehringer Ingelheim Investigational SiteKansas City, Missouri  
Boehringer Ingelheim Investigational SiteLas Vegas, Nevada  
ID CareHillsborough, New Jersey  
Boehringer Ingelheim Investigational SiteSanta Fe, New Mexico  
Albany Medical CollegeAlbany, New York  
University of New York at Stony BrookStony Brook, New York  
Boehringer Ingelheim Investigational SiteHuntersville, North Carolina  
Boehringer Ingelheim Investigational SiteOklahoma City, Oklahoma  
Boehringer Ingelheim Investigational SiteColumbia, South Carolina  
Boehringer Ingelheim Investigational SiteHouston, Texas  
Boehringer Ingelheim Investigational SiteAnnandale, Virginia